Community Bank N.A. Has $101,000 Stock Holdings in Danaher Co. (NYSE:DHR)

Community Bank N.A. reduced its holdings in Danaher Co. (NYSE:DHR) by 9.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 435 shares of the conglomerate’s stock after selling 47 shares during the quarter. Community Bank N.A.’s holdings in Danaher were worth $101,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Nicholas Hoffman & Company LLC. lifted its stake in shares of Danaher by 2.3% in the 4th quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock valued at $439,000 after purchasing an additional 43 shares during the period. Drive Wealth Management LLC grew its position in shares of Danaher by 3.1% in the 4th quarter. Drive Wealth Management LLC now owns 1,485 shares of the conglomerate’s stock worth $344,000 after buying an additional 44 shares during the period. Trust Investment Advisors increased its stake in shares of Danaher by 1.8% in the 4th quarter. Trust Investment Advisors now owns 2,811 shares of the conglomerate’s stock worth $650,000 after acquiring an additional 49 shares in the last quarter. Connolly Sarah T. lifted its position in Danaher by 0.5% during the 3rd quarter. Connolly Sarah T. now owns 9,599 shares of the conglomerate’s stock valued at $2,382,000 after acquiring an additional 50 shares during the period. Finally, Austin Private Wealth LLC boosted its stake in Danaher by 3.4% during the third quarter. Austin Private Wealth LLC now owns 1,566 shares of the conglomerate’s stock worth $389,000 after acquiring an additional 51 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Transactions at Danaher

In related news, Director Teri List sold 3,289 shares of the stock in a transaction that occurred on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the transaction, the director now directly owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The sale was disclosed in a filing with the SEC, which is available through this link. In other Danaher news, Director Teri List sold 3,289 shares of the stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the transaction, the director now owns 19,726 shares in the company, valued at $4,898,360.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the sale, the senior vice president now owns 38,102 shares in the company, valued at $9,601,704. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,957 shares of company stock valued at $8,265,802. 11.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on DHR. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Citigroup lifted their price target on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday. Royal Bank of Canada raised their price objective on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Bank of America upped their target price on shares of Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research note on Wednesday. Finally, Robert W. Baird raised their price target on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday. Six research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $270.00.

Danaher Stock Performance

Shares of NYSE:DHR traded down $3.74 during midday trading on Thursday, hitting $246.67. The company had a trading volume of 1,233,484 shares, compared to its average volume of 2,764,397. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $259.00. The company has a fifty day moving average of $249.00 and a two-hundred day moving average of $230.78. The company has a market cap of $182.67 billion, a price-to-earnings ratio of 42.44, a PEG ratio of 4.24 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.48% and a net margin of 16.78%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. During the same quarter in the prior year, the business posted $2.36 EPS. Danaher’s revenue for the quarter was down 2.6% compared to the same quarter last year. On average, equities research analysts expect that Danaher Co. will post 7.62 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date is Wednesday, March 27th. This is an increase from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio is 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.